Spherix Incorporated (NASDAQ: SPEX) have announced that Frank Reiner has joined the company as vice president of
licensing, where he will report to chief executive Anthony Hayes and play a key role in the company's licensing efforts. 19 March 2014
In an interview with The Pharma Letter, CEO Michael Forer discusses ADC Therapeutics' developing pipeline and intentions to take multiple proprietary ADCs into clinical development. 19 March 2014
The Pharma Letter interviewed chief executive Darren Kelly about Fibrotech’s ethos and its lead product, FT011, an antifibrotic to prevent the tissue fibrosis associated with diabetic nephropathy. 18 March 2014
Avion Pharmaceuticals, a US-based specialty pharmaceutical company, has announced the promotion of Mike Sullivan to the position of president. 18 March 2014
The president of pharma giant Merck & Co’s (NYSE: MRK) operations in Europe and Canada Bruno Strigini spoke about pharma innovation in action at The Economist’s Pharma Summit in London on Thursday. 17 March 2014
Health care is a human right and the pharma industry must evolve to meet future challenges, claims Elias Zerhouni, president of Global R&D at French drug major Sanofi. 14 March 2014
The way pharma works needs to change with an increasing focus on collaborations, sharing data and access to medicines, according to a panel discussion at The Economist’s Pharma Summit in London yesterday. 14 March 2014
Australian product development company Clinical Network Services (CNS) has launched a new UK office headed by Paul Cronin who joins as UK Director and Director, Business Development. 10 March 2014
US headquartered Moderna Therapeutics, a leader in the development of RNA (mRNA) Therapeutics has announced that Lorence Kim will join Moderna's executive leadership team as chief financial officer, effective April 21. 7 March 2014
Aquavit Pharmaceuticals, a private US-based life science company, has announced the appointment of David Goldberg as chief medical officer. 6 March 2014
French biopharmaceutical company Genticel has recruited Sophie Olivier as chief medical officer to lead the clinical development of its pipeline, in particular the ProCervix Phase II trial. 4 March 2014
Australian biotech company Novogen has announced the appointments of new board members and a strategic advisor to support its transition into a clinical-stage company with a growing US presence and an investor base in the USA and Australia. 4 March 2014
Executives are moving back to an ‘ex-directory’ world, where smaller, restricted networks are of the highest value, according to RSA, a global life sciences executive search and interim management specialist. 3 March 2014
Australian biotechnology firm Phosphagenics has appointed biotech industry veterans Lawrence Gozlan, Nathan Drona and Geert Cauwenbergh as non-executive directors, with Mr Gozlan assuming the role of Chairman of the Board on an interim basis. 3 March 2014
Belgium’s largest drugmaker, UCB, yesterday announced a succession plan for its chief excecutive, Roch Doliveux, saying that Jean-Christophe Tellier, currently executive vice president, Biopharma Brands and Solutions, will be appointed chief executive-elect and chairman of the executive committee as of March 1, 2014. 21 February 2014
Germany’s Merck KGaA has appointed Simon Sturge to head the biosimilars unit, effective March 1, succeeding Thierry Hulot, who created the biosimilars unit and took over responsibility for Global Manufacturing & Supply for the Merck Serono division at the end of last year. 20 February 2014
US drug developer Inovio Pharmaceuticals has expanded its senior management team with two appointments to help advance the company's growing pipeline of preclinical and clinical DNA vaccines. 18 February 2014
Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
The shortage of drugs in Russia is deepening, and is currently being observed in almost 70 regions throughout the country and forcing the local state to consider ways to resume stable supplies to local market, reports The Pharma Letter’s local correspondent. 13 August 2024
US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 7 August 2024
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
Domestic drugs and foreign drugs, the production of which is localized in Russia, will be given a priority when included in the list of vital and essential drugs (VED) and expensive drugs, according to a recent resolution signed by the Russian government, The Pharma Letter’s local correspondent reports. 1 August 2024